32 active trials 13 recruiting 15 Phase 3 21 disease areas 17 changes in 30 days
10 trials changed in the last 30 days: 1 stopped, 3 with notable changes, 6 with minor changes only.
Trial terminated
Sponsor's reason: Genmab has decided to discontinue further clinical development of acasunlimab following strategic portfolio prioritization. The decision was not related to safety concerns.
GenmabPhase 2 NCT05117242 Registry history of NCT05117242 on ClinicalTrials.gov (opens the registry)
Updated
Primary endpoint(s) modified
Also in this update: Interventions modified; Trial arms changed: 4 → 5
GenmabPhase 1/2 NCT05579366 Registry history of NCT05579366 on ClinicalTrials.gov (opens the registry)
Updated
Start date pushed from Sep 15, 2026 to Oct 15, 2026
Also in this update: Trial sites expanded: 1 → 4 locations; and 1 more change in the last 30 days
GenmabPhase 3 NCT07775287 Registry history of NCT07775287 on ClinicalTrials.gov (opens the registry)
Updated
Results posted: Sep 30, 2026
GenmabPhase 2 NCT06984328 Registry history of NCT06984328 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 2 → 9 locations
GenmabPhase 3 NCT07564141 Registry history of NCT07564141 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 22 → 34 locations
GenmabPhase 3 NCT07225270 Registry history of NCT07225270 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 171 → 177 locations
GenmabPhase 3 NCT07166094 Registry history of NCT07166094 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 74 → 91 locations
GenmabPhase 2 NCT07288177 Registry history of NCT07288177 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 6 → 17 locations
GenmabPhase 2 NCT07539311 Registry history of NCT07539311 on ClinicalTrials.gov (opens the registry)
Updated
Final enrollment: 584 participants (planned 530)
Also in this update: Primary completion date changed from estimate of Feb 2027 to Aug 18, 2026; Completion moved earlier from May 23, 2028 to Oct 2027
GenmabPhase 3 NCT06619236 Registry history of NCT06619236 on ClinicalTrials.gov (opens the registry)
Updated
| First posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-10-05 | NCT07859215 Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to… | Phase 3 | Not Yet Recruiting |
| Phase 1 | 6 | |
| Phase 1/2 | 7 | |
| Phase 2 | 4 | |
| Phase 3 | 15 |
| NCT ID | Title | Condition | Status | Updated |
|---|---|---|---|---|
| Phase 3 | ||||
| NCT07775287 | Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy… | Colorectal Cancer | Recruiting | 2026-10-09 |
| NCT07564141 | Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to… | Platinum-Sensitive Ovarian Cancer | Recruiting | 2026-10-07 |
| NCT07166094 | Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's… | Endometrial Cancer | Recruiting | 2026-10-06 |
| NCT07225270 | Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to… | Ovarian Cancer | Recruiting | 2026-10-06 |
| NCT07604766 | An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of… | Platinum-resistant Ovarian Cancer | Recruiting | 2026-10-06 |
| NCT07702032 | Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and… | Left-sided Colorectal Cancer | Recruiting | 2026-10-06 |
| NCT06635824 | Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of… | PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC | Active, Not Recruiting | 2026-10-06 |
| NCT07859215 | Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to… | Ovarian Cancer | Not Yet Recruiting | 2026-10-05 |
| NCT06619236 | Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in… | Platinum-resistant Ovarian Cancer | Active, Not Recruiting | 2026-09-28 |
| NCT05578976 | A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined… | Diffuse Large B-Cell Lymphoma | Active, Not Recruiting | 2026-09-11 |
| NCT06191744 | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral… | Follicular Lymphoma (FL) | Active, Not Recruiting | 2026-08-04 |
| NCT05409066 | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral… | Follicular Lymphoma (FL) | Active, Not Recruiting | 2026-07-08 |
| NCT04628494 | A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in… | Diffuse Large B-cell Lymphoma | Active, Not Recruiting | 2026-05-22 |
| NCT07226752 | A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in… | Diffuse Large B-Cell Lymphoma | Active, Not Recruiting | 2026-05-05 |
| NCT06508658 | A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to… | Diffuse Large B-Cell Lymphoma | Active, Not Recruiting | 2026-04-08 |
| Phase 2 | ||||
| NCT07288177 | Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell… | Non-small Cell Lung Cancer (NSCLC) | Recruiting | 2026-10-06 |
| NCT07539311 | Study to Assess the Efficacy and Safety of Rina-S in Participants With Advanced… | Gastrointestinal Cancers | Recruiting | 2026-10-06 |
| NCT05451810 | A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the… | Diffuse Large B-Cell Lymphoma | Active, Not Recruiting | 2026-09-11 |
| NCT05283720 | A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC)… | Non-Hodgkin Lymphoma | Active, Not Recruiting | 2026-07-07 |
| Phase 1/2 | ||||
| NCT05579366 | Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/… | High Grade Epithelial Ovarian Cancer | Recruiting | 2026-10-07 |
| NCT03625037 | First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell… | DLBCL | Active, Not Recruiting | 2026-10-06 |
| NCT04542824 | Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or… | Diffuse Large B Cell Lymphoma | Active, Not Recruiting | 2026-10-06 |
| NCT04623541 | Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic… | Relapsed/Refractory Chronic Lymphocytic Leukemia | Active, Not Recruiting | 2026-10-06 |
| NCT04663347 | Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin… | Diffuse Large B-Cell Lymphoma | Active, Not Recruiting | 2026-10-06 |
| NCT05201248 | A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC)… | B-Cell Non-Hodgkin Lymphoma | Active, Not Recruiting | 2026-09-11 |
Non-Hodgkin Lymphoma (11) · DLBCL (8) · Ovarian Cancer (6) · Follicular Lymphoma (5) · Non-Small Cell Lung Cancer (NSCLC) (4) · Chronic Lymphocytic Leukemia (CLL) (3) · Colorectal Cancer (3) · Lung Cancer (3) · Endometrial Cancer (2) · Leukemia (2)